Dr. Marijana Stojanović

Education: University of Belgrade, Faculty of Chemistry – BSc in Biochemistry (1996); MSc in Biochemistry (field Immunochemistry) (2000); PhD in Biochemistry (field Immunology) (2009)

Career history and research interest: Dr. Marijana Stojanović started her research career at the Immunology Research Center "Branislav Janković," Belgrade, where she entered the field of immunology (1997-1998). She continued her scientific outreach at the Institute of Virology, Vaccines, and Sera "Torlak", Belgrade, where she gained strong expertise in immunology and vaccinology over a period spanning from 1998 to 2023. During this time, her research primarily focused on investigating the impact of various conditions, including adjuvants, immunomodulatory agents, and antigen exposure routes, on subsequent immune responses, particularly in the context of vaccination, autoimmune diseases (such as anti-phospholipid syndrome), and inflammatory conditions (such as ocular chlamydial infections and inflammatory bowel disease). Dr. Stojanović also explored the potential of modulating the severity and progression of inflammatory diseases in animal models by targeting innate immunity with immunomodulators. Additionally, she conducted extensive research on characterizing and validating monoclonal antibodies for their application as alternatives to antisera in cases of suspected tetanus toxin intoxication. Throughout her career, Dr. Stojanović has been actively establishing, implementing, validating, and standardizing various biological assays to assess specific immunological parameters. In 2023, she joined the Department of Molecular Biology at the Institute of Biological Research "Siniša Stanković," University of Belgrade, where her research focus shifted to the immunological aspects of attenuating type 1 diabetes.

Memberships in academic organizations: Serbian Biochemical Society, Immunological Society of Serbia, Serbian Society for Molecular Biology